Although biosimilars have been part of clinical practice for more than a decade, healthcare
professionals (HCPs) do not fully accept them. This is because of the perception that …

Age-related macular degeneration (AMD) is a leading cause of visual impairment and
blindness in older adults. The prognosis for the neovascular type of advanced AMD …

Can Biosimilar Drugs Bring Down Health Care Costs? Biosimilars work like established
therapeutic agents but have some dissimilarities based on differences in production. These …

Biologics have been used increasingly in the treatment and supportive care of cancer;
however, their high cost places a significant burden on healthcare systems. The expiration of …

Background: The global pharma sector is fast shifting from generics to biologics and
biosimilars with the first approval in Europe in 2006 followed by US approval in 2015. In the …

In pharmaceutical research and development, pursuing novel therapeutics and optimizing
existing drugs have been revolutionized by the fusion of cutting-edge technologies and …

Background Biosimilars could be a promising option to help decrease healthcare costs and
expand access to treatment. There is no previous evidence of a global bibliometric analysis …

Objectives Infliximab is increasingly used to treat neurosarcoidosis. We aimed to determine
the efficacy and tolerance of an infliximab biosimilar for treating neurosarcoidosis. Methods …

Background: Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …

Generic Drugs are copies of small chemical drugs identical to their reference drug by dose,
form, safety, strength, mode of administration, quality, performance, and intended purpose …